Literature DB >> 31693911

Structural Basis and Kinetic Pathway of RBM39 Recruitment to DCAF15 by a Sulfonamide Molecular Glue E7820.

Xinlin Du1, Oleg A Volkov2, Robert M Czerwinski2, HuiLing Tan2, Carlos Huerta2, Emily R Morton2, Jim P Rizzi2, Paul M Wehn2, Rui Xu2, Deepak Nijhawan3, Eli M Wallace2.   

Abstract

E7820 and indisulam are two examples of aryl sulfonamides that recruit RBM39 to Rbx-Cul4-DDA1-DDB1-DCAF15 E3 ligase complex, leading to its ubiquitination and degradation by the proteasome. To understand their mechanism of action, we performed kinetic analysis on the recruitment of RBM39 to DCAF15 and solved a crystal structure of DDA1-DDB1-DCAF15 in complex with E7820 and the RRM2 domain of RBM39. E7820 packs in a shallow pocket on the surface of DCAF15 and the resulting modified interface binds RBM39 through the α1 helix of the RRM2 domain. Our kinetic studies revealed that aryl sulfonamide and RBM39 bind to DCAF15 in a synergistic manner. The structural and kinetic studies confirm aryl sulfonamides as molecular glues in the recruitment of RBM39 and provide a framework for future efforts to utilize DCAF15 to degrade other proteins of interest.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DCAF15; E7820; PROTAC; RBM39; indisulam; molecular glue; sulfonamide; targeted protein degradation

Mesh:

Substances:

Year:  2019        PMID: 31693911     DOI: 10.1016/j.str.2019.10.005

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  24 in total

Review 1.  Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic.

Authors:  Zhenyi Hu; Craig M Crews
Journal:  Chembiochem       Date:  2021-09-23       Impact factor: 3.461

Review 2.  Dysregulation and therapeutic targeting of RNA splicing in cancer.

Authors:  Robert F Stanley; Omar Abdel-Wahab
Journal:  Nat Cancer       Date:  2022-05-27

3.  Rational discovery of molecular glue degraders via scalable chemical profiling.

Authors:  Sophie Bauer; Matthias Brand; Cristina Mayor-Ruiz; Zuzanna Kozicka; Marton Siklos; Hana Imrichova; Ines H Kaltheuner; Elisa Hahn; Kristina Seiler; Anna Koren; Georg Petzold; Michaela Fellner; Christoph Bock; André C Müller; Johannes Zuber; Matthias Geyer; Nicolas H Thomä; Stefan Kubicek; Georg E Winter
Journal:  Nat Chem Biol       Date:  2020-08-03       Impact factor: 15.040

4.  Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation.

Authors:  Lu Lv; Peihao Chen; Longzhi Cao; Yamei Li; Zhi Zeng; Yue Cui; Qingcui Wu; Jiaojiao Li; Jian-Hua Wang; Meng-Qiu Dong; Xiangbing Qi; Ting Han
Journal:  Elife       Date:  2020-08-17       Impact factor: 8.140

Review 5.  Roles and mechanisms of alternative splicing in cancer - implications for care.

Authors:  Sophie C Bonnal; Irene López-Oreja; Juan Valcárcel
Journal:  Nat Rev Clin Oncol       Date:  2020-04-17       Impact factor: 66.675

Review 6.  Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.

Authors:  Tao Wu; Hojong Yoon; Yuan Xiong; Sarah E Dixon-Clarke; Radosław P Nowak; Eric S Fischer
Journal:  Nat Struct Mol Biol       Date:  2020-06-15       Impact factor: 15.369

Review 7.  Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide.

Authors:  Max Jan; Adam S Sperling; Benjamin L Ebert
Journal:  Nat Rev Clin Oncol       Date:  2021-03-02       Impact factor: 66.675

8.  Ligandability of E3 Ligases for Targeted Protein Degradation Applications.

Authors:  Bridget P Belcher; Carl C Ward; Daniel K Nomura
Journal:  Biochemistry       Date:  2021-09-02       Impact factor: 3.162

Review 9.  Ubiquitin ligases in cancer: Functions and clinical potentials.

Authors:  Shanshan Duan; Michele Pagano
Journal:  Cell Chem Biol       Date:  2021-05-10       Impact factor: 9.039

Review 10.  Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class.

Authors:  Francesca D'Amico; Rishov Mukhopadhyay; Huib Ovaa; Monique P C Mulder
Journal:  Chembiochem       Date:  2021-03-18       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.